Amir Mortazavi, MD
College of Medicine
Molecular Carcinogenesis and Chemoprevention
Cancer, Urinary Bladder Cancer, Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Chronic, B-Cell, Weight Loss, Colorectal Cancer, Carcinoma, Renal Cell, Anorexia, Leukemia, Promyelocytic, Acute
Amir Mortazavi, MD, is a member of the Molecular Carcinogenesis and Chemoprevention Program at the OSUCCC – James, where his research focuses on epigenetic modifications and experimental therapeutics for genitourinary cancers.One of his recent research projects suggests that sorafenib, an oral multikinase inhibitor, could have off-target effects on cytokine-induced signal transduction in immune effector cells. Dr. Mortazavi has co-authored many articles in well-respected publications, including Cancer Chemotherapy and Pharmacology, Journal of Immunology, Journal of Proteome Research and Journal of Magnetic Resonance Imaging.